 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
| «12345678 |
- Arcalyst (rilonacept) / Regeneron, Kiniksa
Trial completion, Enrollment change, Trial primary completion date: Inflammation in Chronic Kidney Disease and Cardiovascular Disease - The Role of Genetics and Interleukin-1 Receptor Antagonist (IL-1ra) (clinicaltrials.gov) - Jul 21, 2015
P=N/A, N=15, Completed, Sponsor: Department of Veterans Affairs
Recruiting --> Completed | N=54 --> 15 | Trial primary completion date: Dec 2016 --> Feb 2015
- Arcalyst (rilonacept) / Regeneron, Kiniksa
Enrollment closed, Enrollment change: Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA) (clinicaltrials.gov) - Jun 3, 2015
P2, N=6, Active, not recruiting, Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting --> Completed | N=54 --> 15 | Trial primary completion date: Dec 2016 --> Feb 2015 Recruiting --> Active, not recruiting | N=15 --> 6
- Arcalyst (rilonacept) / Regeneron, Kiniksa
Enrollment open, Trial primary completion date: Interleukin-1 Trap to Treat Vascular Dysfunction in Chronic Kidney Disease (CKD) (clinicaltrials.gov) - May 21, 2015
P4, N=38, Recruiting, Sponsor: University of Colorado, Denver
Recruiting --> Active, not recruiting | N=15 --> 6 Active, not recruiting --> Recruiting | Trial primary completion date: Dec 2014 --> Dec 2016
- ||| mavrilimumab (KPL-301) / Kiniksa
Enrollment closed: A Long Term Safety Study of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - May 12, 2015
P2, N=400, Active, not recruiting, Sponsor: MedImmune LLC
Active, not recruiting --> Recruiting | Trial primary completion date: Dec 2014 --> Dec 2016 Recruiting --> Active, not recruiting
- |||| mavrilimumab (KPL-301) / Kiniksa
Trial completion, Enrollment change: A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 26, 2015
P2, N=215, Completed, Sponsor: MedImmune LLC
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=120 --> 215
- | Arcalyst (rilonacept) / Regeneron, Kiniksa
Trial initiation date, Trial primary completion date: Cold Contact Urticaria Treatment With Rilonacept (clinicaltrials.gov) - Feb 5, 2015
P2, N=20, Recruiting, Sponsor: Charite University, Berlin, Germany
Active, not recruiting --> Completed | N=120 --> 215 Initiation date: Jun 2014 --> Jan 2015 | Trial primary completion date: May 2015 --> Apr 2016
- | mavrilimumab (KPL-301) / Kiniksa
Trial completion, Enrollment change: A Double-blind, Placebo-controlled, Single-dose Study to Evaluate the PK, IM, and Safety in Japanese Subjects (clinicaltrials.gov) - Jan 9, 2015
P1, N=39, Completed, Sponsor: MedImmune LLC
Initiation date: Jun 2014 --> Jan 2015 | Trial primary completion date: May 2015 --> Apr 2016 Active, not recruiting --> Completed | N=24 --> 39
- mavrilimumab (KPL-301) / Kiniksa
Enrollment closed, Enrollment change: A Double-blind, Placebo-controlled, Single-dose Study to Evaluate the PK, IM, and Safety in Japanese Subjects (clinicaltrials.gov) - Dec 10, 2014
P1, N=24, Active, not recruiting, Sponsor: MedImmune LLC
Active, not recruiting --> Completed | N=24 --> 39 Recruiting --> Active, not recruiting | N=60 --> 24
- Arcalyst (rilonacept) / Regeneron, Kiniksa
Enrollment closed: Interleukin-1 Trap to Treat Vascular Dysfunction in Chronic Kidney Disease (CKD) (clinicaltrials.gov) - Dec 6, 2014
P4, N=38, Active, not recruiting, Sponsor: University of Colorado, Denver
Recruiting --> Active, not recruiting | N=60 --> 24 Recruiting --> Active, not recruiting
- || mavrilimumab (KPL-301) / Kiniksa
Trial primary completion date: A Long Term Safety Study of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Nov 3, 2014
P2, N=400, Recruiting, Sponsor: MedImmune LLC
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2020 --> Dec 2015
- ||| mavrilimumab (KPL-301) / Kiniksa
Enrollment change: A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Nov 3, 2014
P2, N=120, Active, not recruiting, Sponsor: MedImmune LLC
Trial primary completion date: Jan 2020 --> Dec 2015 N=215 --> 120
- Arcalyst (rilonacept) / Regeneron, Kiniksa
Trial completion, Enrollment change: Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young Adults (clinicaltrials.gov) - Sep 16, 2014
P2, N=71, Completed, Sponsor: Montefiore Medical Center
N=215 --> 120 Active, not recruiting --> Completed | N=100 --> 71
- Arcalyst (rilonacept) / Regeneron, Kiniksa
Trial primary completion date: Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA) (clinicaltrials.gov) - Aug 25, 2014
P2, N=15, Recruiting, Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Active, not recruiting --> Completed | N=100 --> 71 Trial primary completion date: Jan 2016 --> Jun 2016
- ||| mavrilimumab (KPL-301) / Kiniksa
New P1 trial: A Double-blind, Placebo-controlled, Single-dose Study to Evaluate the PK, IM, and Safety in Japanese Subjects (clinicaltrials.gov) - Aug 11, 2014
P1, N=60, Recruiting, Sponsor: MedImmune LLC
- ||| mavrilimumab (KPL-301) / Kiniksa
Enrollment closed, Enrollment change: A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Aug 6, 2014
P2, N=215, Active, not recruiting, Sponsor: MedImmune LLC
Trial primary completion date: Jan 2016 --> Jun 2016 Recruiting --> Active, not recruiting | N=172 --> 215
- Arcalyst (rilonacept) / Regeneron, Kiniksa
Trial completion, Enrollment change, Trial primary completion date: Rilonacept (Arcalyst ®) in the Treatment of Subacromial Bursitis (clinicaltrials.gov) - Aug 4, 2014
P=N/A, N=33, Completed, Sponsor: Keesler Air Force Base Medical Center
Recruiting --> Active, not recruiting | N=172 --> 215 Recruiting --> Completed | N=150 --> 33 | Trial primary completion date: Mar 2015 --> Mar 2014
- | Arcalyst (rilonacept) / Regeneron, Kiniksa
New P2 trial: Cold Contact Urticaria Treatment With Rilonacept (clinicaltrials.gov) - Jun 26, 2014
P2, N=20, Recruiting, Sponsor: Charite University, Berlin, Germany
- | Arcalyst (rilonacept) / Regeneron, Kiniksa
Enrollment open: Cold Contact Urticaria Treatment With Rilonacept (clinicaltrials.gov) - Jun 26, 2014
P2, N=20, Recruiting, Sponsor: Charite University, Berlin, Germany
Recruiting --> Completed | N=150 --> 33 | Trial primary completion date: Mar 2015 --> Mar 2014 Not yet recruiting --> Recruiting
- Arcalyst (rilonacept) / Regeneron, Kiniksa
Trial primary completion date: Interleukin-1 Trap to Treat Vascular Dysfunction in Chronic Kidney Disease (CKD) (clinicaltrials.gov) - May 19, 2014
P4, N=38, Recruiting, Sponsor: University of Colorado, Denver
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2014 --> Dec 2014
- Arcalyst (rilonacept) / Regeneron, Kiniksa
Trial completion date: Interleukin-1 Trap to Treat Vascular Dysfunction in Chronic Kidney Disease (CKD) (clinicaltrials.gov) - May 19, 2014
P4, N=38, Recruiting, Sponsor: University of Colorado, Denver
Trial primary completion date: Jul 2014 --> Dec 2014 Trial completion date: Jul 2014 --> Dec 2014
- ||| mavrilimumab (KPL-301) / Kiniksa
Enrollment change: A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis (clinicaltrials.gov) - Apr 8, 2014
P2, N=422, Completed, Sponsor: MedImmune LLC
Trial completion date: Jul 2014 --> Dec 2014 N=280 --> 422
- |||| mavrilimumab (KPL-301) / Kiniksa
Trial completion: A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis (clinicaltrials.gov) - Apr 8, 2014
P2, N=422, Completed, Sponsor: MedImmune LLC
N=280 --> 422 Active, not recruiting --> Completed
- | Arcalyst (rilonacept) / Regeneron, Kiniksa
Trial completion: Interleukin-1 Trap to Treat Autoinflammatory Diseases (clinicaltrials.gov) - Mar 5, 2014
P2, N=11, Completed, Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Arcalyst (rilonacept) / Regeneron, Kiniksa
Trial completion: RID-A: Rilonacept in Diabetes Mellitus Type 1: Safety Study (clinicaltrials.gov) - Feb 20, 2014
P1, N=13, Completed, Sponsor: University of Texas Southwestern Medical Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| mavrilimumab (KPL-301) / Kiniksa
Enrollment change: A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Feb 5, 2014
P2, N=172, Recruiting, Sponsor: MedImmune LLC
Active, not recruiting --> Completed N=120 --> 172
- | Arcalyst (rilonacept) / Regeneron, Kiniksa
New P2 trial: A Safety and Efficacy Study of Mycophenolate Mofetil and Rilonacept in Patients With Alcoholic Hepatitis (clinicaltrials.gov) - Jul 17, 2013
P2, N=186, Not yet recruiting, Sponsor: Timothy Morgan, MD
- Arcalyst (rilonacept) / Regeneron, Kiniksa
Enrollment open: Inflammation in Chronic Kidney Disease and Cardiovascular Disease - The Role of Genetics and Interleukin-1 Receptor Antagonist (IL-1ra) (clinicaltrials.gov) - Jun 19, 2013
P=N/A, N=54, Recruiting, Sponsor: Department of Veterans Affairs
N=120 --> 172 Not yet recruiting --> Recruiting
- |||| mavrilimumab (KPL-301) / Kiniksa
Enrollment open: A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 6, 2013
P2, N=172, Recruiting, Sponsor: MedImmune LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Arcalyst (rilonacept) / Regeneron, Kiniksa
New P1 trial: Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA) (clinicaltrials.gov) - Feb 28, 2013
P1, N=24, Completed, Sponsor: Regeneron Pharmaceuticals
- Arcalyst (rilonacept) / Regeneron, Kiniksa
New P2 trial: Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA) (clinicaltrials.gov) - Feb 26, 2013
P2, N=15, Recruiting, Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- ||| mavrilimumab (KPL-301) / Kiniksa
Trial initiation date: A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Jan 15, 2013
P2, N=172, Recruiting, Sponsor: MedImmune LLC
Not yet recruiting --> Recruiting Initiation date: Nov 2012 --> Mar 2013
- Arcalyst (rilonacept) / Regeneron, Kiniksa
Trial completion: Rilonacept for Treatment of Familial Mediterranean Fever (FMF) (clinicaltrials.gov) - Oct 28, 2012
P2, N=14, Completed, Sponsor: The Cleveland Clinic
Initiation date: Nov 2012 --> Mar 2013 Active, not recruiting --> Completed
- ||||| mavrilimumab (KPL-301) / Kiniksa
New P2 trial: A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Oct 25, 2012
P2, N=172, Recruiting, Sponsor: MedImmune LLC
- Arcalyst (rilonacept) / Regeneron, Kiniksa
Trial initiation date: Inflammation in Chronic Kidney Disease and Cardiovascular Disease - The Role of Genetics and Interleukin-1 Receptor Antagonist (IL-1ra) (clinicaltrials.gov) - Oct 24, 2012
P=N/A, N=54, Recruiting, Sponsor: Department of Veterans Affairs
Active, not recruiting --> Completed Initiation date: Mar 2012 --> Jan 2013
- ||||| mavrilimumab (KPL-301) / Kiniksa
New P2 trial: A Long Term Safety Study of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Oct 21, 2012
P2, N=400, Recruiting, Sponsor: MedImmune LLC
- |||| mavrilimumab (KPL-301) / Kiniksa
Trial completion: A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Oct 16, 2012
P2, N=291, Completed, Sponsor: MedImmune LLC
Initiation date: Mar 2012 --> Jan 2013 Recruiting --> Completed
- ||||| mavrilimumab (KPL-301) / Kiniksa
New P2 trial: A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis (clinicaltrials.gov) - Oct 11, 2012
P2, N=422, Completed, Sponsor: MedImmune LLC
- | Arcalyst (rilonacept) / Regeneron, Kiniksa
Trial termination: UPSURGE: Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares (clinicaltrials.gov) - Oct 1, 2012
P3, N=219, Terminated, Sponsor: Regeneron Pharmaceuticals
Recruiting --> Completed Recruiting --> Terminated
- | Arcalyst (rilonacept) / Regeneron, Kiniksa
Enrollment change: UPSURGE: Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares (clinicaltrials.gov) - Oct 1, 2012
P3, N=219, Terminated, Sponsor: Regeneron Pharmaceuticals
Recruiting --> Terminated N=350 --> 219
- Arcalyst (rilonacept) / Regeneron, Kiniksa
New P4 trial: Interleukin-1 Trap to Treat Vascular Dysfunction in Chronic Kidney Disease (CKD) (clinicaltrials.gov) - Aug 9, 2012
P4, N=38, Recruiting, Sponsor: University of Colorado, Denver
- mavrilimumab (KPL-301) / Kiniksa
Trial initiation date: A Single Dose Study of the CAM-3001 in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Jul 18, 2012
P1, N=38, Completed, Sponsor: MedImmune Ltd
N=350 --> 219 Initiation date: Oct 2007 --> Oct 2008
- Arcalyst (rilonacept) / Regeneron, Kiniksa
Enrollment closed: Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young Adults (clinicaltrials.gov) - Jul 8, 2012
P2, N=100, Active, not recruiting, Sponsor: Montefiore Medical Center
Initiation date: Oct 2007 --> Oct 2008 Recruiting --> Active, not recruiting
- | Arcalyst (rilonacept) / Regeneron, Kiniksa
Biomarker, New P1/2 trial: IL1-TRAP, Rilonacept, in Systemic Sclerosis (clinicaltrials.gov) - Feb 22, 2012
P1/2, N=40, Recruiting, Sponsor: Boston University
- | mavrilimumab (KPL-301) / Kiniksa
Trial completion: A Single Dose Study of the CAM-3001 in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Nov 1, 2011
P1, N=38, Completed, Sponsor: MedImmune Ltd
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Arcalyst (rilonacept) / Regeneron, Kiniksa
New P3 trial: UPSURGE: Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares (clinicaltrials.gov) - Oct 24, 2011
P3, N=219, Terminated, Sponsor: Regeneron Pharmaceuticals